Report from Extraordinary General Meeting of Vitrolife AB (publ)

At Vitrolife's Extraordinary General Meeting on October 20, 2021, decisions were made to facilitate the acquisition of Igenomix through a non-cash consideration issue.

Rhea-AI Summary

At Vitrolife's Extraordinary General Meeting on October 20, 2021, decisions were made to facilitate the acquisition of Igenomix through a non-cash consideration issue. Additionally, Vesa Koskinen was elected as a new board member, resulting in an increase in board remuneration due to the expanded membership. These decisions are contingent upon the successful completion of the non-cash issue.

Positive

• Acquisition of Igenomix is expected to enhance Vitrolife's market position.
• Appointment of a new board member may bring fresh perspectives.

Negative

• Increased board remuneration could raise operational costs for shareholders.
• Dependence on the non-cash issue's successful execution poses financial risks.

Argus Session date unavailable

+131.15% session move Open Argus

Details

News Market Reaction – VTRLY

The recorded move for VTRLY in the trading session of this news was +131.15%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GOTHENBURG, Sweden, Oct. 20, 2021 /PRNewswire/ -- At Vitrolife's Extraordinary General Meeting today, the following, amongst other things, was decided:

• Non-cash consideration issue in accordance with the board's proposal with the purpose of financing the acquisition of Igenomix.
• Vesa Koskinen, partner at EQT, is elected new board member and the board is thus expanded with one member. The board remuneration is increased because of the additional member. The decision is conditional on the non-cash issue being carried out.

Gothenburg, October 20, 2021
VITROLIFE AB (publ)
The Board

Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

The information was submitted for publication, through the agency of the contact person set out above, at 4.00 pm CET on October 20, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/report-from-extraordinary-general-meeting-of-vitrolife-ab--publ-,c3436805

The following files are available for download:

https://mb.cision.com/Main/1031/3436805/1483649.pdf

Report from EGM

 

View original content:https://www.prnewswire.com/news-releases/report-from-extraordinary-general-meeting-of-vitrolife-ab-publ-301404741.html

SOURCE Vitrolife AB (publ)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What decisions were made at Vitrolife's Extraordinary General Meeting on October 20, 2021?

The meeting approved a non-cash consideration issue for the acquisition of Igenomix and elected Vesa Koskinen as a new board member.

How does the acquisition of Igenomix impact Vitrolife's business?

The acquisition is anticipated to strengthen Vitrolife's market presence, enhancing its growth potential.

What is the significance of the new board member election for VTRLY?

The election of Vesa Koskinen may bring new insights and strategies to Vitrolife's management.

What are the financial implications of the board remuneration increase?

The increase in board remuneration may lead to higher operational costs, impacting shareholder returns.